Trials / Completed
CompletedNCT04314934
OLE of Phase 2b/3 Study ANAVEX2-73-AD-004
Open Label Extension Study for Patients With Early Alzheimer's Disease (AD) Enrolled in Study ANAVEX2-73-AD-004
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 300 (actual)
- Sponsor
- Anavex Life Sciences Corp. · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2b/3 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and effficacy of daily treatment.
Detailed description
This is a Phase 2b/3 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and effficacy of daily treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ANAVEX2-73 | Oral capsules |
Timeline
- Start date
- 2019-10-10
- Primary completion
- 2024-06-14
- Completion
- 2024-06-14
- First posted
- 2020-03-19
- Last updated
- 2024-08-12
Locations
51 sites across 5 countries: Australia, Canada, Germany, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT04314934. Inclusion in this directory is not an endorsement.